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Background
Approximately 30% of HIV-infected patients are co-
infected with hepatitis C (HCV). The current treatment
standard of care for HCV, pegylated interferon and riba-
virin (RBV), has demonstrated a sustained virologic
response (SVR) in less than 50% of HCV/HIV co-
infected patients, and only 17-35% in HCV genotype 1
patients. It has been previously shown that using a
weight-based RBV dose results in favorable SVR rates.
Prior studies suggest that HCV/HIV co-infected patients
receiving a HAART regimen that included tenofovir
(TDF) had higher SVR rates than those who received
abacavir (ABC) in their nucleos(t)ide analogue (N(t)RTI)
backbone.
Purpose of the study
At our specialty clinic for the treatment of HCV/HIV
co-infected patients, we re-examined the efficacy of
HCV treatment in patients receiving either agent in
their regimen with weight-based ribavirin doses.
Methods
Patients with HIV/HCV co-infection (HCV genotype 1)
met with a multidisciplinary team before therapy initia-
tion for education and teaching. HCV treatment con-
sisted of weekly injections of 180 mcg pegylated
interferon subcutaneously and weight-based dosing of
RBV (13mg/kg/day to maximum of 1200 mg/day).
Treatment duration was 48 weeks with longer treatment
in slow responders; side effects and adverse events were
treated promptly. The HAART regimen consisted of a
N(t)RTI backbone with either ABC or TDF and a
protease inhibitor or non-NRTI. We retrospectively
compared SVR rates in patients being treated with
either ABC or TDF.
Results
Thirty-four patients met the inclusion criteria. In an
ITT analysis, 20 of 34 (59%) patients receiving HAART
demonstrated SVR with no significant differences
between races (p=0.31). Among those twenty HAART
patients with SVR, 9 patients were being treated with
ABC and 11 were being treated with TDF (p=0.13). The
length of treatment between ABC and TDF treated
groups did not differ significantly (49.6 and 49.5 weeks,
p=0.001). No significant difference in SVR rates was
shown between the two groups.
Conclusions
The rate of SVR in patients with HIV/HCV genotype 1
dosed with weight-based RBV was significantly higher
than generally reported. There was no difference in SVR
rates in HIV/HCV co-infected patients receiving ABC or
TDF in their HAART regimen with weight-based RBV.
These results may give providers flexibility in their
selection of N(t)RTI backbone while receiving treatment
for HCV.
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